Insight Molecular Diagnostics Inc.
IMDXNASDAQHealthcare● Active
$5.72
+$0.48(+9.16%)
Market Cap$153533168
P/E Ratio—
52W High$8.51
52W Low$2.33
Insight Molecular Diagnostics Inc. (IMDX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IMDX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.05M | $1.88M | $1.50M | $0.96M | $2.20M |
| Cost of Revenue | $3.87M | $1.14M | $1.09M | $0.98M | $0.78M |
| Gross Profit | $0.19M | $0.74M | $0.41M | ($0.02M) | $1.42M |
| Gross Margin %(computed) | 4.69% | 39.34% | 27.48% | -1.88% | 64.60% |
| Operating Expenses | |||||
| R&D Expenses | $15.90M | $9.84M | $9.29M | $7.30M | $5.04M |
| G&A Expenses | $10.63M | $13.14M | $12.98M | $21.52M | $20.39M |
| Total Operating Expenses | $30.77M | $61.78M | $25.55M | $17.98M | $55.15M |
| Operating Income | ($30.58M) | ($61.04M) | ($25.14M) | ($18.00M) | ($53.73M) |
| Operating Margin %(computed) | -754.08% | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.11M | $0.08M | $0.05M | $0.08M | $0.21M |
| Income Before Tax | ($50.22M) | ($60.66M) | ($24.86M) | ($18.61M) | ($52.87M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | ($9.26M) |
| Net Income | ($50.22M) | ($60.66M) | ($27.78M) | ($72.90M) | ($64.10M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.65 | $-4.66 | $-3.75 | $-20.00 | $-14.40 |
| Wtd Avg Shares | 30.48M | 13.07M | 7.65M | 5.54M | 4.45M |
| EBITDA | ($28.38M) | ($59.02M) | ($23.12M) | ($13.31M) | ($48.46M) |
| EBITDA Margin %(computed) | -699.90% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Insight Molecular Diagnostics Inc. data
About Insight Molecular Diagnostics Inc. (IMDX) Income Statement
Insight Molecular Diagnostics Inc. (IMDX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IMDX reported revenue of $0.00B, gross profit of $0.00B (gross margin 4.69%), and net income of ($0.05B) — a net profit margin of -1238.52%.
Frequently asked questions
IMDX · 4 questionsInsight Molecular Diagnostics Inc. (IMDX) reported revenue of $0.00B for 2025, up 115.6% year-over-year.
IMDX revenueIMDX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08